Ortanol (Omeprazole)

• Ortanol (omeprazole) is indicated for several acid‑related disorders where suppression of gastric acid provides therapeutic benefit.
• Gastroesophageal reflux disease (GERD): alleviates heartburn and regurgitation, promotes healing of erosive esophagitis, and reduces acid exposure.
• Peptic ulcer disease: facilitates ulcer healing in the stomach and duodenum by maintaining a higher gastric pH.
• Helicobacter pylori eradication (in combination therapy): enhances the efficacy of antibiotics by creating a less acidic environment for bacterial clearance.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors, reducing ulcer risk.

• Omeprazole is a benzimidazole derivative that binds covalently to cysteine residues on the H+/K+ ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. This irreversible inhibition blocks the final step of acid secretion, leading to a prolonged reduction of gastric acidity for up to 72 hours after a single dose and allows the gastric mucosa to recover from acid‑induced injury.

Omeprazole is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects

• Headache: mild to moderate pain often transient.
• Diarrhea: loose stools that may resolve with continued therapy.
• Nausea: feeling of queasiness, especially after first doses.
• Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Clostridioides difficile infection: severe colitis presenting with watery diarrhea.
• Low magnesium (hypomagnesemia): muscle cramps, irregular heartbeat, seizures in prolonged use.

When prescribing or dispensing Ortanol, several precautionary measures should be observed to ensure safe use.

• Assess renal function: adjust therapy in patients with severe renal impairment.
• Monitor magnesium levels: prolonged treatment may cause hypomagnesemia.
• Evaluate for hypersensitivity: discontinue immediately if allergic signs appear.
• Use caution in elderly: increased risk of bone fractures with long‑term use.
• Store at room temperature: keep in the original container, protect from moisture.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines; awareness of key interactions helps avoid therapeutic failures or toxicity.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet activation leading to decreased efficacy.
• Atorvastatin and other CYP2C19 substrates: increased plasma concentrations and risk of adverse effects.
• High‑dose methotrexate: impaired renal clearance may raise toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR and bleeding risk.
• Digoxin: elevated serum levels may cause toxicity.
• Diazepam: enhanced sedation due to higher drug exposure.